The CR2 monoclonal antibody is produced by immunizing mice with a synthesized peptide derived from human CD21 protein. Hybridoma cells, generated by fusing mouse B cells with myeloma cells, are screened for CR2 antibody production. The monoclonal antibody is subsequently affinity-purified from mouse ascites using a specific immunogen via affinity chromatography. This antibody is suitable for recognizing human CR2 protein in ELISA and IHC applications.
CR2, also known as CD21, is a transmembrane protein primarily expressed on the surface of B-cells. Its primary function involves binding and processing complement-coated antigens, facilitating their presentation to T-cells and thereby initiating an immune response. Notably, CD21 also serves as a receptor for the Epstein-Barr virus, playing a crucial role in viral entry and infection.
Monoclonal antibodies (mAbs) are laboratory-produced molecules engineered to serve as substitute antibodies that can restore, enhance, or mimic the immune system’s attack on cells . They are produced by identical immune cells that are all clones of a unique parent cell . Monoclonal antibodies can be classified based on their source and structure:
Monoclonal antibodies exhibit several key biological properties:
Monoclonal antibodies play crucial roles in the immune system:
Monoclonal antibodies interact with other molecules and cells through various mechanisms:
The expression and activity of monoclonal antibodies are tightly regulated:
Monoclonal antibodies have a wide range of applications in biomedical research and medicine: